Oncology Data Advisor

In this episode of Exploring Artificial Intelligence in Oncology, Wanmei Ou, PhD, the Vice President of Product, Clinical Decision Support, & Analytics Data Platform at Ontada, shares more about Ontada’s collaboration with Microsoft to transform unstructured oncology data with Azure OpenAI technology. Her discussion with Dr. Waqas Haque highlights how AI is transforming clinical workflows, reducing documentation burdens, and driving improved patient outcomes.

The FDA's recent accelerated approval of zanidatamab marks a significant breakthrough in the treatment landscape for human epidermal growth factor receptor 2 (HER2)–positive biliary tract cancer (BTC). Following the approval, Dr. James Harding, Associate Attending Physician in the Gastrointestinal Oncology and Early Drug Development Services at Memorial Sloan Kettering Cancer Center, sat down to provide oncology clinicians with insights into its significance and implications for clinical practice.

As Lung Cancer Awareness Month progresses, this discussion hosted by Oncology Data Advisor sheds light on the advancements in lung cancer therapies, unmet needs, the evolving landscape of molecular testing, and actionable insights for clinicians.

Gain valuable insights into the complexities of diagnosing and managing dedifferentiated liposarcoma (DDLPS) and earn free CME credit with our latest podcast. This episode features expert guidance from Dr. Richard F. Riedel of Duke University and Dr. Candace L. Haddox of Dana-Farber Cancer Institute. Delve into the latest on identifying MDM2 and CDK4 amplification, challenges in diagnosing DDLPS, and updates on emerging therapies like CDK4/6 inhibitors and immunotherapies. Learn how a multidisciplinary approach enhances patient outcomes in this rare and aggressive soft tissue sarcoma. Listen now and advance your expertise! Click here to claim your CME credit: i3health.com/course-information/podcast-ddlps

The BENEFIT trial, which studied isatuximab, lenalidomide, dexamethasone, and bortezomib in transplant-ineligible multiple myeloma, was published earlier this year in Nature Medicine. I'll be talking about this as if it was one of my patients coming to me with a copy of this paper in their hand that a friend or loved one forwarded to them. What do I tell them?

Artera: Personalizing Treatment Decisions in Prostate Cancer and Beyond With Waqas Haque, MD, MPH, and Trevor Royce, MD, MS, MPH, FASCO by i3 Health

i3 Health is pleased to invite you to Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care, a free, live webinar held on November 7 at 10:00 am Eastern and November 19 at 11:30 am Eastern. This interview features an exclusive preview from the two webinar co-chairs, Dr. Filipa Lynce, Director of the Inflammatory Breast Center at Dana-Farber Cancer Center and Assistant Professor of Medicine at Harvard Medical School, and Catherine Skefos, Certified Genetic Counselor in the Clinical Cancer Genetics Program at the University of Texas MD Anderson Cancer Center. Click below to register for this insightful webinar and enhance your understanding of genetic testing and counseling in cancer care! Register for the webinar: https://i3health.com/course-information/pathways-to-precision-integrating-genetic-counseling-and-testing-into-cancer-care

In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque, MD, sits down with Aamir Ehsan, MD, the Founder and CEO of CorePath Laboratories in San Antonio, Texas. Together they discuss how CorePath utilizes AI in pathology.

Dr. Deborah Wong, Director of the Medical Oncology Program and Clinical Trials Program for Head and Neck Squamous Cell Cancers (HNSCC) and an Associate Clinical Professor of Medicine at the University of California Los Angeles (UCLA) is currently serving as co-chair of i3 Health’s accredited CME/NCPD activity, Recurrent and Metastatic HNSCC, Harnessing Immunotherapy and Comprehensive Care. With new developments in the field occurring over recent months, Dr. Wong sat down with us again to share new updates in treatment and management of HNSCC. Click here for the full activity: https://i3health.com/course-information/hnscc-harnessing-immunotherapy-in-comprehensive-care

Jeff Sperry, PharmD, BCPS, a Clinical Pharmacist at UCHealth Memorial Hospital, discusses additional advances in chronic kidney disease since recording the i3Health CPE-accredited activity, Slowing Progression of Chronic Kidney Disease Through Value-Based Care. Following the interview, continue listening for the complete CPE-accredited podcast. Click this link to claim your free CPE certificate: https://i3health.com/course-information/chronic-kidney-disease

Listen now to this CME-accredited podcast, part of the Multiple Myeloma Task Force series, where we will explore strategies for mitigating disease burden and addressing health care disparities in patients with relapsed/refractory multiple myeloma. This session brings together expert insights from Task Force Co-Chairs, Dr. Sikander Ailawadhi, Professor of Medicine at Mayo Clinic, and Dr. Rahul Banerjee, Assistant Professor of Medical Oncology at Fred Hutchinson Cancer Center and the University of Washington. Their consensus-driven perspectives will provide valuable guidance on improving patient outcomes and equity in care for multiple myeloma. To learn more about the task force, read the position statement or revisit the youtube live please visit: https://i3health.com/course-information/podcast-rrmm

Click here to view the full activity and claim free NCPD credit! https://i3health.com/course-information/managing-immune-related-adverse-events-to-ensure-optimal-cancer-immunotherapy-outcomes-the-nurses-view At last year’s Greater Los Angeles Oncology Nursing Society (GLAONS) Oncology Care Summit, i3 Health hosted a nursing continuing professional development (NCPD) symposium entitled Managing Immune-Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes (IRAEs): The Nurse’s View, chaired by Blanca Ledezma, MSN, NP, AOCNP®, Hematology/Oncology Nurse Practitioner at UCLA Health. With numerous advances in the immunotherapy space occurring since the symposium was held, Oncology Data Advisor Editorial Board member Beth Sandy, MSN, CRNP, Outpatient Thoracic Oncology Nurse Practitioner at the University of Pennsylvania Abramson Cancer Center, sat down to discuss some of these updates in lung cancer and her own insights on optimal management of IRAEs from the nursing perspective.

In this episode of Exploring Artificial Intelligence (AI) in Oncology, Dr. Waqas Haque sits down with Dana Brown, the President, CEO, and Chairman of the Board at iCAD, a company whose mission is to use innovative AI solutions that empower providers to accurately, reliably, and quickly detect cancer and improve outcomes. Ms. Brown shares more about iCAD’s products and recommendations for how to integrate AI into the clinic, including: • Her own background in the technology industry and why she joined iCAD • The products and solutions that iCAD offers • How iCAD utilizes AI to improve mammography accuracy • The ProFound Breast Health Suite and how it enhances cancer detection and patient outcomes • Their recent partnership with Densitas and CancerIQ and their impact on breast health • What distinguishes iCAD’s AI algorithms from other solutions in the market • The importance of company culture in driving success of AI startups and defining traits behind iCAD’s success • Recommendations for clinicians in prac

Claim free CME credit at: https://i3health.com/course-information/mced-3 Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application. In Module 3 of our CME podcast, Dr. Charles Vega, Clinical Professor of Family Medicine at the University of California, Irvine, will explore the practical implementation of multicancer early detection (MCED) tests into clinical practice, offering valuable insights into how these innovations could transform cancer screening and improve patient outcomes.

Claim free CME credit at https://i3health.com/course-information/MCED-2 Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application. Join Dr. Charles Vega in Module 2 of our CME podcast as he delves into the cutting-edge world of multicancer early detection (MCED) tests. With nearly 2 million new cancer cases expected in 2024, the role of early detection has never been more critical. Dr. Vega will unpack the latest clinical trial data on MCED tests for gynecologic, gastrointestinal, and hematologic cancers, exploring their potential to revolutionize cancer screening and improve patient outcomes.

Claim free CME credit at https://i3health.com/course-information/mced-1 Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application. Listen to Module 1 and join Dr. Charles Vega, a distinguished Clinical Professor of Family Medicine at the University of California, Irvine, as he explores the cutting-edge realm of multicancer early detection (MCED). Dr. Vega will delve into the scientific foundations of blood-based cancer screening, highlighting both current limitations and the promising potential of MCED technologies. Learn how these revolutionary tests harness biomarkers to detect multiple cancers in a single, convenient screening—a game-changer in overcoming barriers like low awareness and limited access to screening facilities.

In this Fellows Forum podcast episode, Dr. Richa Thakur, Palliative Care Physician and Hematology/Oncology Fellow at Northwell Health, speaks with Dr. Janet Abrahm, one of the founders of the field of palliative care in the United States. Dr. Abrahm shares insights into her career and research in palliative care, including: • How palliative care in oncology isn’t just for end of life—it’s for enhancing patient outcomes • How palliative care serves as a partner for the oncology team • The value of palliative care training for hematology/oncology fellows • How to cope with the moral distress and compassion fatigue that clinicians may experience when treatment doesn’t work for their patients • The stages of grief (denial, anger, bargaining, depression, acceptance) and how they can be experienced by both patients and clinicians • The importance for both oncology and palliative care fellows to find an outlet for their grief • Dr. Abrahm’s website and book, “Comprehensive Guide to Supportive and Palliative Car

In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque sits down with Luis Valente, CEO and Co-Founder of iLoF, a digital health company pioneering a breakthrough AI platform to accelerate the future of personalized drug discovery and development.

In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque sits down with Dr. Tamir Wolf, Co-Founder and CEO of Theator, a company pioneering next-generation AI and computer vision technology to automatically capture and analyze surgical data in real time to generate actionable insights and improve surgical outcomes.

In this podcast, hear expert perspectives on practice-changing advances in the treatment and personalized management of patients with hemophilia from Dr. Guy Young, Director of the Hemostasis and Thrombosis Program, Attending Physician in Hematology/Oncology, and Professor of Pediatrics at Keck School of Medicine of USC; and Dr. Jennifer Davila, Co-Director of the Hemophilia Treatment Center at Montefiore and Associate Professor of Pediatrics at The Children's Hospital at Montefiore. Listen to the episode now! Click here to claim your free CME/NCPD credit for this activity: https://bit.ly/4eQSbaL